IRIS Accounts Production v24.3.0.553 02414239 Board of Directors 1.4.23 31.3.24 31.3.24 wholesale of chemical products. false true true false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh024142392023-03-31024142392024-03-31024142392023-04-012024-03-31024142392022-03-31024142392022-04-012023-03-31024142392023-03-3102414239ns15:EnglandWales2023-04-012024-03-3102414239ns14:PoundSterling2023-04-012024-03-3102414239ns10:Director12023-04-012024-03-3102414239ns10:PrivateLimitedCompanyLtd2023-04-012024-03-3102414239ns10:SmallEntities2023-04-012024-03-3102414239ns10:Audited2023-04-012024-03-3102414239ns10:SmallCompaniesRegimeForDirectorsReport2023-04-012024-03-3102414239ns10:SmallCompaniesRegimeForAccounts2023-04-012024-03-3102414239ns10:FullAccounts2023-04-012024-03-3102414239ns10:Director22023-04-012024-03-3102414239ns10:CompanySecretary12023-04-012024-03-3102414239ns10:RegisteredOffice2023-04-012024-03-3102414239ns5:CurrentFinancialInstruments2024-03-3102414239ns5:CurrentFinancialInstruments2023-03-3102414239ns5:Non-currentFinancialInstruments2024-03-3102414239ns5:Non-currentFinancialInstruments2023-03-3102414239ns5:ShareCapital2024-03-3102414239ns5:ShareCapital2023-03-3102414239ns5:RevaluationReserve2024-03-3102414239ns5:RevaluationReserve2023-03-3102414239ns5:RetainedEarningsAccumulatedLosses2024-03-3102414239ns5:RetainedEarningsAccumulatedLosses2023-03-3102414239ns5:ShareCapital2022-03-3102414239ns5:RetainedEarningsAccumulatedLosses2022-03-3102414239ns5:RevaluationReserve2022-03-3102414239ns5:RetainedEarningsAccumulatedLosses2022-04-012023-03-3102414239ns5:RevaluationReserve2022-04-012023-03-3102414239ns5:RetainedEarningsAccumulatedLosses2023-04-012024-03-3102414239ns5:RevaluationReserve2023-04-012024-03-3102414239ns5:LandBuildings2023-03-3102414239ns5:PlantMachinery2023-03-3102414239ns5:LandBuildings2023-04-012024-03-3102414239ns5:PlantMachinery2023-04-012024-03-3102414239ns5:LandBuildings2024-03-3102414239ns5:PlantMachinery2024-03-3102414239ns5:LandBuildings2023-03-3102414239ns5:PlantMachinery2023-03-3102414239ns5:CurrentFinancialInstrumentsns5:WithinOneYear2024-03-3102414239ns5:CurrentFinancialInstrumentsns5:WithinOneYear2023-03-3102414239ns5:WithinOneYear2024-03-3102414239ns5:WithinOneYear2023-03-3102414239ns5:BetweenOneFiveYears2024-03-3102414239ns5:BetweenOneFiveYears2023-03-3102414239ns5:AllPeriods2024-03-3102414239ns5:AllPeriods2023-03-3102414239ns5:RevaluationReserve2023-03-31
REGISTERED NUMBER: 02414239 (England and Wales)











BIODEG CHEMICAL CO LTD

REPORT OF THE DIRECTORS AND

FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2024






BIODEG CHEMICAL CO LTD (REGISTERED NUMBER: 02414239)

CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024










Page

Company Information 1

Report of the Directors 2

Report of the Independent Auditors 3 to 6

Income Statement 7

Balance Sheet 8

Statement of Changes in Equity 9

Notes to the Financial Statements 10 to 15


BIODEG CHEMICAL CO LTD

COMPANY INFORMATION
FOR THE YEAR ENDED 31 MARCH 2024







DIRECTORS: P Tarleton
M Short





SECRETARY: P Tarleton





REGISTERED OFFICE: Walker House
Exchange Flags
Liverpool
L2 3YL





REGISTERED NUMBER: 02414239 (England and Wales)





AUDITORS: UHY Calvert Smith LLP
Statutory Auditor
Chartered Accountants
Heritage House
Murton Way
Osbaldwick
York
North Yorkshire
YO19 5UW

BIODEG CHEMICAL CO LTD (REGISTERED NUMBER: 02414239)

REPORT OF THE DIRECTORS
FOR THE YEAR ENDED 31 MARCH 2024


The directors present their report with the financial statements of the company for the year ended 31 March 2024.

DIRECTORS
The directors shown below have held office during the whole of the period from 1 April 2023 to the date of this report.

P Tarleton
M Short

STATEMENT OF DIRECTORS' RESPONSIBILITIES
The directors are responsible for preparing the Report of the Directors and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing these financial statements, the directors are required to:

-select suitable accounting policies and then apply them consistently;
-make judgements and accounting estimates that are reasonable and prudent;
-prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

STATEMENT AS TO DISCLOSURE OF INFORMATION TO AUDITORS
So far as the directors are aware, there is no relevant audit information (as defined by Section 418 of the Companies Act 2006) of which the company's auditors are unaware, and each director has taken all the steps that he ought to have taken as a director in order to make himself aware of any relevant audit information and to establish that the company's auditors are aware of that information.

AUDITORS
The auditors, UHY Calvert Smith LLP, will be proposed for re-appointment at the forthcoming Annual General Meeting.

This report has been prepared in accordance with the provisions of Part 15 of the Companies Act 2006 relating to small companies.

ON BEHALF OF THE BOARD:





P Tarleton - Director


25 September 2024

REPORT OF THE INDEPENDENT AUDITORS TO THE MEMBERS OF
BIODEG CHEMICAL CO LTD


Opinion
We have audited the financial statements of Biodeg Chemical Co Ltd (the 'company') for the year ended 31 March 2024 which comprise the Income Statement, Balance Sheet, Statement of Changes in Equity and Notes to the Financial Statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).
_
In our opinion the financial statements:
-give a true and fair view of the state of the company's affairs as at 31 March 2024 and of its profit for the year then ended;
-have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
-have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion
We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern
In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Other information
The directors are responsible for the other information. The other information comprises the information in the Report of the Directors, but does not include the financial statements and our Report of the Auditors thereon.

Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006
In our opinion, based on the work undertaken in the course of the audit:
- the information given in the Report of the Directors for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the Report of the Directors has been prepared in accordance with applicable legal requirements.

REPORT OF THE INDEPENDENT AUDITORS TO THE MEMBERS OF
BIODEG CHEMICAL CO LTD


Matters on which we are required to report by exception
In the light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the Report of the Directors.

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:
- adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of directors' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit; or
- the directors were not entitled to prepare the financial statements in accordance with the small companies regime and take advantage of the small companies' exemption from the requirement to prepare a Strategic Report or in preparing the Report of the Directors.

Responsibilities of directors
As explained more fully in the Statement of Directors' Responsibilities set out on page two, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.

REPORT OF THE INDEPENDENT AUDITORS TO THE MEMBERS OF
BIODEG CHEMICAL CO LTD


Auditors' responsibilities for the audit of the financial statements
Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue a Report of the Auditors that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in
line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including
fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

- we identified the laws and regulations applicable to the company through discussions with directors and from our
commercial knowledge and experience of the sector; and
- we focused on specific laws and regulations which we considered may have a direct material effect on the financial statements or the operations of the company, including the Companies Act 2006, taxation, employment, and health and safety legislation.

We assessed the susceptibility of the company's financial statements to material misstatement, including obtaining an understanding of how fraud might occur by:

- making enquiries of management as to where they considered there was susceptibility to fraud, their knowledge of
actual, suspected and alleged fraud; and
- considering the internal controls in place to mitigate risks of fraud and non-compliance with laws and regulations.

To address the risk of fraud through management bias and override of controls, we:

- performed analytical procedures to identify any unusual or unexpected relationships;
- tested journal entries to identify unusual transactions;
- assessed whether judgements and assumptions made in determining the accounting estimates set out in note 2
were indicative of potential bias; and
- investigated the rationale behind significant or unusual transactions.

In response to the risk of irregularities and non-compliance with laws and regulations, we designed procedures which included, but were not limited to:

- agreeing financial statement disclosures to underlying supporting documentation; and
- reading the minutes of meetings of those charged with governance; and
- enquiring of management as to actual and potential litigation and claims.

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including
those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk
increases the more that compliance with a law or regulation is removed from the events and transactions reflected
in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is
also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at www.frc.org.uk/auditorsresponsibilities. This description forms part of our Report of the Auditors.

REPORT OF THE INDEPENDENT AUDITORS TO THE MEMBERS OF
BIODEG CHEMICAL CO LTD


Use of our report
This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in a Report of the Auditors and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.




Harry Howley ACA MAAT (Senior Statutory Auditor)
for and on behalf of UHY Calvert Smith LLP
Statutory Auditor
Chartered Accountants
Heritage House
Murton Way
Osbaldwick
York
North Yorkshire
YO19 5UW

17 October 2024

BIODEG CHEMICAL CO LTD (REGISTERED NUMBER: 02414239)

INCOME STATEMENT
FOR THE YEAR ENDED 31 MARCH 2024

2024 2023
£    £   

TURNOVER 1,889,282 2,171,888

Cost of sales 303,010 520,123
GROSS PROFIT 1,586,272 1,651,765

Administrative expenses 1,386,770 1,367,814
OPERATING PROFIT and
PROFIT BEFORE TAXATION 199,502 283,951

Tax on profit 48,651 61,185
PROFIT FOR THE FINANCIAL YEAR 150,851 222,766

BIODEG CHEMICAL CO LTD (REGISTERED NUMBER: 02414239)

BALANCE SHEET
31 MARCH 2024

2024 2023
Notes £    £    £    £   
FIXED ASSETS
Tangible assets 4 734,790 645,203

CURRENT ASSETS
Stocks 71,444 70,104
Debtors 5 223,739 461,073
Cash at bank 293,017 144,110
588,200 675,287
CREDITORS
Amounts falling due within one year 6 189,406 155,768
NET CURRENT ASSETS 398,794 519,519
TOTAL ASSETS LESS CURRENT LIABILITIES 1,133,584 1,164,722

CREDITORS
Amounts falling due after more than one
year

7

(100,000

)

(100,000

)

PROVISIONS FOR LIABILITIES (72,425 ) (54,414 )
NET ASSETS 961,159 1,010,308

CAPITAL AND RESERVES
Called up share capital 102 102
Revaluation reserve 10 60,865 60,865
Retained earnings 900,192 949,341
961,159 1,010,308

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the Board of Directors and authorised for issue on 25 September 2024 and were signed on its behalf by:





P Tarleton - Director


BIODEG CHEMICAL CO LTD (REGISTERED NUMBER: 02414239)

STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 MARCH 2024

Called up
share Retained Revaluation Total
capital earnings reserve equity
£    £    £    £   
Balance at 1 April 2022 102 726,575 60,865 787,542

Changes in equity
Total comprehensive income - 222,766 - 222,766
Balance at 31 March 2023 102 949,341 60,865 1,010,308

Changes in equity
Dividends - (200,000 ) - (200,000 )
Total comprehensive income - 150,851 - 150,851
Balance at 31 March 2024 102 900,192 60,865 961,159

BIODEG CHEMICAL CO LTD (REGISTERED NUMBER: 02414239)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024


1. STATUTORY INFORMATION

Biodeg Chemical Co Limited is a private company, limited by shares, registered in the UK.

The address of its registered office is Walker House, Exchange Flags, Liverpool, United Kingdom, L2 3YL, and its principal place of business is Corner Site, Edwards Lane, Speke, Liverpool, Merseyside, L24 9HW.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Going concern
The directors have considered the financial position and trading projections of the company, and have a reasonable expectation that the company has adequate resources to continue to trade into the foreseeable future. The company therefore continues to adopt the going concern basis in preparing the financial statements.

Related party exemption
The company has taken advantage of exemption, under the terms of Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland', not to disclose related party transactions with wholly owned subsidiaries within the group.

Significant judgements and estimates
There have been no significant judgements or estimates made in the preparation of these financial statements.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services.

Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have transferred to the buyer. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.

BIODEG CHEMICAL CO LTD (REGISTERED NUMBER: 02414239)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2024


2. ACCOUNTING POLICIES - continued

Tangible fixed assets
Tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses.

Depreciation is calculated to write down the cost less estimated residual value of all tangible fixed assets over their expected useful lives, using the straight-line method. The rates applicable are:

- Land and buildings 2% on cost
- Plant and machinery 25% on cost and 10% on cost

At each reporting date fixed assets are reviewed to determine whether there is any indication that those assets have suffered an impairment loss. If there is an indication of possible impairment, the recoverable amount of any affected asset is estimated and compared with its carrying amount. If estimated recoverable amount is lower, the carrying amount is reduced to its estimated recoverable amount, and an impairment loss is recognised immediately in profit or loss.

If an impairment loss subsequently reverses, the carrying amount of the asset is increased to the revised estimate of its recoverable amount, but not in excess of the amount that would have been determined had no impairment loss been recognised for the asset in prior years. A reversal of an impairment loss is recognised immediately in profit or loss.

Stocks
Stocks are valued at the lower of cost and net realisable value using the FIFO method. Cost comprises expenditure incurred in the normal course of business in bringing the stocks to their present location and condition.

BIODEG CHEMICAL CO LTD (REGISTERED NUMBER: 02414239)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2024


2. ACCOUNTING POLICIES - continued

Financial instruments
The company only enters into basic financial instruments transactions that result in the recognition of financial assets and liabilities like trade and other accounts receivable and payable and loans from banks.

Debt instruments (other than those wholly repayable or receivable within one year), including loans and other accounts receivable and payable are initially measured at present value of the future cash flows and subsequently at amortised cost using the effective interest method. Debt instruments that are payable or receivable within one year typically trade payables or receivables, are measured, initially and subsequently, at the undiscounted amount of the cash or other consideration, expected to be paid or received. However, if the arrangements of a short-term instrument constitute a financing transaction, like the payment of a trade debt deferred beyond normal business terms or financed at a rate of interest that is not a market rate or in case of an out-right short-term loan not at market rate, the financial asset or liability is measured, initially, at the present value of the future cash flow discounted at a market rate of interest for a similar debt instrument and subsequently at amortised cost.

For financial assets measured at amortised cost, the impairment loss is measured as the difference between an asset's carrying amount and the present value of estimated cash flows discounted at the asset's original effective interest rate. If a financial asset has a variable interest rate, the discount rate for measuring any impairment loss is the current effective interest rate determined under the contract.

For financial assets measured at cost less impairment, the impairment loss is measured as the difference between and asset's carrying amount and best estimate, which is an approximation of the amount that the group would receive for the asset if it were to be sold at the balance sheet date.

Financial assets and liabilities are offset and the net amount reported in the balance sheet when there is an enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all material timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Foreign currencies
Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Any gain or loss arising from a change in exchange rates subsequent to the date of the transaction is included as an exchange gain or loss in the statement of comprehensive income.

BIODEG CHEMICAL CO LTD (REGISTERED NUMBER: 02414239)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2024


2. ACCOUNTING POLICIES - continued

Pensions
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

The company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the company pays fixed contributions into a separate entity. Once the contributions have been paid the company has no further payment obligations.

The contributions are recognised as an expense in the statement of comprehensive income when they fall due. Amounts not paid are shown in accruals as a liability in the balance sheet. The assets of the plan are held separately from the company in independently administered funds.

Dividends
Equity dividends are recognised when they become legally payable. Interim equity dividends are recognised when paid. Final equity dividends are recognised when approved by the shareholders at an annual general
meeting.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 16 (2023 - 16 ) .

4. TANGIBLE FIXED ASSETS
Plant and
Land and machinery
buildings etc Totals
£    £    £   
COST
At 1 April 2023 500,000 784,020 1,284,020
Additions - 154,218 154,218
At 31 March 2024 500,000 938,238 1,438,238
DEPRECIATION
At 1 April 2023 140,285 498,532 638,817
Charge for year 6,000 58,631 64,631
At 31 March 2024 146,285 557,163 703,448
NET BOOK VALUE
At 31 March 2024 353,715 381,075 734,790
At 31 March 2023 359,715 285,488 645,203

BIODEG CHEMICAL CO LTD (REGISTERED NUMBER: 02414239)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2024


5. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£    £   
Trade debtors 192,229 409,472
Amounts owed by group undertakings 250 -
Other debtors 31,260 51,601
223,739 461,073

6. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£    £   
Trade creditors 71,315 34,788
Taxation and social security 84,542 112,011
Other creditors 33,549 8,969
189,406 155,768

7. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR
2024 2023
£    £   
Other creditors 100,000 100,000

8. LEASING AGREEMENTS

Minimum lease payments under non-cancellable operating leases fall due as follows:
2024 2023
£    £   
Within one year 2,405 4,080
Between one and five years - 680
2,405 4,760

9. SECURED DEBTS

There is a fixed and floating charge over all property and assets of the company in favour of National Westminster Bank plc.

10. RESERVES
Revaluation
reserve
£   
At 1 April 2023
and 31 March 2024 60,865

Revaluation reserve - this reserve records the value of asset revaluations on transition to FRS102.
The revaluation reserve is a non-distributable reserve.

BIODEG CHEMICAL CO LTD (REGISTERED NUMBER: 02414239)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2024


11. ULTIMATE CONTROLLING PARTY

The ultimate parent undertaking of this company (from 31 January 2024) is MKR Holdings Limited, a company incorporated in England and Wales. The smallest group in which the results of the company are consolidated is that headed by Meade-King, Robinson & Company Limited. The address of its registered office is Walker House, Exchange Flags, Liverpool, United Kingdom, L2 3YL. Copies of the financial statements of Meade-King, Robinson & Company Limited are available to the public via Companies House.